Skip to main content
Premium Trial:

Request an Annual Quote

Resumption Recommendation Expected

Officials in the US are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine, the Washington Post reports.

Officials from the Food and Drug Administration and Centers for Disease Control and Prevention recommended earlier this month that inoculations with J&J's vaccine be paused while they investigated reports of rare, but serious blood clots combined with low blood platelet levels.

According to the Post, officials are expected to recommend that a new warning statement about the possibility of the rare complication be added to fact sheets about the vaccine. It notes that that would be in line with what European regulators announced earlier this week. The European Medicines Agency said that though the vaccine may be associated with an increased risk of blood clots, its benefit of preventing COVID-19 outweighs the risk.

The Post adds that an official announcement is expected following the meeting Friday of a CDC advisory panel.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.